RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment
Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months
ODAC Votes 13:0 For Approving Perjeta
Early Treatment with CMX001 Can Help Prevent CMV Infection
Researchers Identify Mutation Linked to Inherited Risk of ALL
Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia
Avoiding the Hippocampus During Whole-Brain Radiotherapy Can Preserve Memory Function
Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy
Long-term Hormonal Therapy Adds No Additional Benefits
NCI CTEP Approved Trials For the Month of September
FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Brown University reaches agreement with Trump administration to restore funding
- Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC
